HIGHLIGHTS
- who: (HSPG et al. from the University of California, Davis, United Wakayama Medical University, Japan have published the research: Small-molecule compound from AlphaScreen disrupts tau-glycan interface, in the Journal: (JOURNAL)
- what: This approach has been applied to target crucial interactions in a variety of diseases, such as Spike/ACE2 interaction in SARS-CoV-2 (Hanson et_al, 2020) and RNA-protein interaction (Baker et_al, 2021) in tauopathies. Using a ThT fluorescence assay (Zhou et_al, 2022), the authors demonstrate that A9 can inhibit heparin-induced tau aggregation in a dose-dependent manner . The authors report . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.